Allogene Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0197701065

SecurityALLO / Allogene Therapeutics, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership1,285,702 shares
Latest Disclosed Value $ 3,137,113
Northern Trust Corp reports 7.28% increase in ownership of ALLO / Allogene Therapeutics, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 1,285,702 shares of Allogene Therapeutics, Inc. (US:ALLO) valued at $3,137,113 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,198,467 shares of Allogene Therapeutics, Inc.. This represents a change in shares of 7.28% during the quarter. The current value of the position is $2,622,832 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 1,285,702 87,235 7.28 3,137 91.16 0.0004
2026-02-17 2025-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 1,198,467 -81,161 -6.34 1,642 3.47 0.0002
2025-11-14 2025-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 1,279,628 5,336 0.42 1,587 10.22 0.0002
2025-08-13 2025-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 1,274,292 79,882 6.69 1,440 -17.44 0.0002
2025-05-13 2025-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 1,194,410 -110,822 -8.49 1,744 -37.30 0.0003
2025-02-14 2024-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 1,305,232 56,693 4.54 2,780 -20.46 0.0004
2024-11-13 2024-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 1,248,539 210,434 20.27 3,496 44.54 0.0006
2024-08-14 2024-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 1,038,105 67,038 6.90 2,419 -44.29 0.0004
2024-05-14 2024-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 971,067 -43,278 -4.27 4,341 33.29 0.0007
2024-02-13 2023-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 1,014,345 153,818 17.87 3,256 19.40 0.0006
2023-11-13 2023-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 860,527 -1,979 -0.23 2,728 -36.37 0.0005
2023-08-11 2023-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 862,506 63,333 7.92 4,287 8.59 0.0008
2023-05-15 2023-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 799,173 -31,231 -3.76 3,948 -24.43 0.0008
2023-02-13 2022-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 830,404 -335,206 -28.76 5,223 -58.51 0.0011
2022-11-14 2022-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 1,165,610 413,301 54.94 12,588 46.78 0.0029
2022-08-12 2022-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 752,309 53,229 7.61 8,576 34.67 0.0018
2022-05-13 2022-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 699,080 -25,637 -3.54 6,368 -41.11 0.0011
2022-02-08 2021-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 724,717 11,215 1.57 10,813 -41.03 0.0018
2021-11-15 2021-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 713,502 -21,592 -2.94 18,336 -4.36 0.0032
2021-08-13 2021-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 735,094 86,630 13.36 19,172 -16.24 0.0034
2021-05-12 2021-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 648,464 -20,143 -3.01 22,890 35.64 0.0043
2021-02-11 2020-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 668,607 -12,980 -1.90 16,875 -34.35 0.0033
2020-11-16 2020-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 681,587 8,969 1.33 25,703 -10.76 0.0056
2020-08-14 2020-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 672,618 154,124 29.73 28,803 185.77 0.0068
2020-05-14 2020-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 518,494 6,479 1.27 10,079 -24.23 0.0029
2020-02-14 2019-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 512,015 -15,965 -3.02 13,302 -7.56 0.0030
2019-11-13 2019-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 527,980 216,959 69.76 14,390 72.31 0.0034
2019-08-13 2019-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 311,021 20,971 7.23 8,351 -0.41 0.0020
2019-05-13 2019-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 290,050 3,810 1.33 8,385 8.77 0.0021
2019-02-12 2018-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 286,240 286,240 7,709 0.0022
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.